ClinicalTrials.gov
public full text
Public Domain
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App(NL) (-G-F) Mice.#319053
- SRSF1 as a promising biomarker and key player in the pathogenesis of Alzheimer's disease.#143117
- Gesteigerte neuronale Funktionsstörungen durch Alzheimer Immuntherapien / Aylin Derya Keskin-Dargin ; Gutachter: Arthur Konnerth, Benedikt Wiestler ; Betreuer: Arthur Konnerth#970333
- Neuroinflammation in Alzheimer disease.#159956
- Cognitive Training and Brain Stimulation in Patients With Post-COVID-19 Cognitive Impairment#995267
Record · ID 913813
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive